Becton, Dickinson and Company lures Elkins from AstraZeneca to be CFO
Becton, Dickinson and Company today announced the appointment of David V. Elkins as Executive Vice President and Chief Financial Officer, effective December 1, 2008.Mr. Elkins, 40, will be responsible for executive management and oversight of BD’s global financial operations. He joins BD from AstraZeneca, where he has served since 2006 as Vice President, Chief Financial Officer, North America and Global Marketing, a $13 billion business. John Considine will continue to be responsible for Integrated Supply Chain; Information Technology; Environment, Health and Safety; Project Management and Engineering Services; and Security.
“We are very pleased to welcome David as a member of our executive management team in this key role,” said Ed Ludwig. “He brings to BD a wealth of deep and diverse experience in global finance and healthcare. We look forward to leveraging his insight and expertise as we continue to implement our strategy of driving revenue growth through innovation, complemented by driving operating effectiveness and productivity.”
Among Mr. Elkins’ prior roles during his 12-year career with AstraZeneca are service as Chief Financial Officer, U.K.; Senior Finance Director – Gastrointestinal and Respiratory; Assistant Treasurer; Senior Finance Manager – Product Strategy and Business Development; Biotechnology Finance Manager; and Regional Finance Manager – Asia.
Mr. Elkins obtained his B.S. degree in economics from the University of Delaware, his MBA from Drexel University and his M.S. degree in Organizational Dynamics from the University of Pennsylvania. He serves on the Audit Committee of the University of Delaware and the Board of the United Way of Delaware.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world.BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.